Table 2.

Dose-Related Response to Norovirus GI.1 and GII.4 Virus-Like Particles in Healthy Adults Aged 18–49 Years in Cohort A, by Results of Enzyme-Linked Immunosorbent Assay of the Total Immunoglobulin Response

Group	Subjects, No.	G1.1							GII.4
		Day 0	Day 28			Day 56			Day 0	Day 28			Day 56
		GMT	GMT	GMFRa	Subjects, %b	GMT	GMFRa	Subjects, %b	GMT	GMT	GMFRa	Subjects, %b	GMT	GMFRa	Subjects, %b
Placebo	8	1396	1280	1.2	0	1974	1.4	25	5583	6451	1.4	13	11 167	2.0	13
Vaccine dose
5 µg	9	3763	222 952	59.3	100	206 425	54.9	100	11 945	70 225	5.9	56	75 848	6.3	56
15 µg	8	2348	126 338	53.8	100	148 394	70.7	100	3948	40 960	10.4	88	60 866	10.8	86
50 µg	10	2560	216 188	84.4	100	176 957	64.0	100	1470	38 217	26.0	80	47 781	21.8	89
150 µg	7	2153	194 840	90.5	100	150 242	69.8	100	28 963	275 545	9.5	75	212 474	7.3	75

Times correspond to before (day 0) and 4 weeks after the first dose (day 28) and 4 weeks after the second dose (day 56).

Abbreviation: GMT, geometric mean titer.

^a Geometric mean fold rise (GMFR) is defined as the geometric mean of the ratio between the titer on the given day and the titer at baseline.

^b Defined as the percentage with a ≥4-fold increase in titer from baseline.